BioSpace News Archive

DTN, the leading provider for actionable weather insights, today announces its expanded partnership with Esri, the world leader in location intelligence

The global vascular endothelial growth factor inhibitors market size is poised to reach USD 10.2 billion by 2023, according to a new report by Technavio, progressing at a CAGR of more than 8% during the forecast period.

iSchemaView, the worldwide leader in advanced imaging for stroke, has received registration approval under the Japanese Pharmaceutical Affairs Law through third party review by the Japanese Association for the Advancement of Medical Equipment for its RAPID imaging platform.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, commercially launched DEXYCU® (dexamethasone intraocular suspension) 9% in March 2019 in the United States. DEXYCU is the first and only U.S. Food and Drug Administration (FDA) approved intraocular steroid

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today new clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA’s platform immunotherapy targeting cancer stem cells

Kraig Biocraft Laboratories, Inc., the leading developer of spider silk based fibers, announces that the Company will be holding its 2019 annual shareholder meeting on Wednesday, July 24, at 10 a.m. EDT, at the East Lansing Marriott at University place, located at 300 M.A.C.

Providence St. Joseph Health, in partnership with Microsoft, will develop and deploy new health care technologies that will harness the power of Microsoft Azure and AI with clinical expertise to transform the care experience

Cardinal Health plans to release fourth-quarter and year-end financial results for its fiscal year 2019 on August 8 prior to the opening of trading on the New York Stock Exchange.

When a child needs recurring diagnostic x-rays, parents often worry about exposure to radiation.

Acquisition further strengthens portfolio of best in class, proprietary enabling solutions for cell and gene therapy companies